Qiagen stock holds near recent levels as earnings metrics guide the story

Qiagen (NL0012169213) is trading on its latest published earnings backdrop, with the most recent reported metrics showing revenue, margin, and cash flow trends as the main reference points for the stock. Without a fresh event in the available search results, the latest verified financial figures remain the clearest way to frame Qiagen stock.

Latest reported numbers

Qiagen reported revenue of EUR 482.6 million in the second quarter of 2025, while adjusted diluted earnings per share came in at $0.55 for the same period. The company also reported an adjusted operating income margin of 31.9% in Q2 2025, giving investors a concrete profitability marker to compare with earlier periods.

Cash generation added another dated reference point: Qiagen reported net cash from operating activities of EUR 146.3 million in the first half of 2025. That was a clear operating metric, not just a headline earnings number, and it matters because cash flow often determines how durable a margin profile is.

Revenue 482.6 million

The second-quarter 2025 revenue figure of EUR 482.6 million gives a direct base for comparison, and the adjusted diluted EPS of $0.55 shows how that revenue translated into profit. The 31.9% adjusted operating income margin in the same quarter suggests the business kept a solid earnings profile even as the market looks for the next update.

Qiagen also said first-half 2025 net cash from operating activities reached EUR 146.3 million, which helps offset any single-quarter noise. For investors, the contrast between quarterly sales, quarterly margin, and half-year cash flow is the most useful reading of the company at this stage.

What the quarter showed

Qiagen stock is therefore being judged on a small set of dated reference points: EUR 482.6 million in Q2 2025 revenue, $0.55 in adjusted diluted EPS, 31.9% adjusted operating income margin, and EUR 146.3 million in first-half operating cash flow. The key comparison is internal and concrete: the company delivered a margin in the low-30% range while still generating meaningful cash in the first half.

That combination matters more than broad sector language. A business that can convert quarterly sales into a 31.9% adjusted operating margin and EUR 146.3 million of operating cash flow has a different earnings profile from one that grows only on revenue momentum.

Product line lens

Qiagen's product portfolio spans sample technologies, assays, and bioinformatics tools, and that mix is central to how the company monetizes recurring demand in life sciences and molecular diagnostics. The latest numbers matter because they indicate how well that portfolio translated into quarterly revenue and cash generation in Q2 2025 and the first half of 2025.

For a company like Qiagen, the product discussion is not separate from the financial discussion. Revenue of EUR 482.6 million, EPS of $0.55, and operating cash flow of EUR 146.3 million are the operational lens through which the product base is being valued.

Stock level to watch

Qiagen shares do not have a fresh dated price in the available search results, so the practical market reference is the latest verified earnings set rather than a live quote. On that basis, the stock case currently rests on Q2 2025 revenue, margin, and cash flow rather than a single-day trading move.

Market context remains earnings led

Qiagen stock is being read through a earnings-first lens, with the latest visible numbers pointing to EUR 482.6 million in Q2 2025 revenue and EUR 146.3 million in first-half 2025 operating cash flow. The Q2 2025 adjusted diluted EPS of $0.55 and adjusted operating margin of 31.9% give the market a dated profitability benchmark until the next report arrives.